Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03511664
Recruitment Status : Active, not recruiting
First Posted : April 30, 2018
Last Update Posted : June 8, 2021
Sponsor:
Information provided by (Responsible Party):
Endocyte

Tracking Information
First Submitted Date  ICMJE April 13, 2018
First Posted Date  ICMJE April 30, 2018
Last Update Posted Date June 8, 2021
Actual Study Start Date  ICMJE May 23, 2018
Actual Primary Completion Date January 27, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 23, 2021)
  • Overall Survival (OS) [ Time Frame: From date of randomization until date of death from any cause, assessed up to 32 months (actual final OS analysis) ]
    OS is defined as time to death due to any cause
  • Radiographic progression-free survival (rPFS) [ Time Frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 32 months (actual final OS analysis) ]
    rPFS is defined as the time to radiographic progression by PCWG3-modified RECIST v1.1 or death.
Original Primary Outcome Measures  ICMJE
 (submitted: April 26, 2018)
Overall Survival [ Time Frame: Every 6-8 weeks until end of treatment and every 3 months during long term follow up [up to 24 months ]
Overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/standard of care
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 23, 2021)
  • Number of participants with Treatment Emergent Adverse Events [ Time Frame: From randomization till 30 days safety follow-up, assessed up to 32 months (actual final OS analysis) ]
    The distribution of adverse events (AE) will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.
  • Overall Response Rate (ORR) [ Time Frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 32 months (actual final OS analysis) ]
    ORR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) according to PCWG3 modified RECIST 1.1
  • Disease control rate (DCR) [ Time Frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 32 months (actual final OS analysis) ]
    DCR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) in soft tissue according to PCWG3 modified RECIST 1.1
  • Duration of Response (DOR) [ Time Frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 32 months (actual final OS analysis) ]
    DOR is defined as the duration of time between the date of first documented response (CR or PR) in soft tissue according to PCWG3 modified RECIST 1.1, and the date of first documented progression or death due to any cause
  • Time to first Symptomatic Skeletal Event (SSE) [ Time Frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 32 months (actual final OS analysis) ]
    Time to SSE is defined as the date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first
  • Progression-free survival (PFS) [ Time Frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 32 months (actual final OS analysis) ]
    PFS is defined as the time from date of randomization to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first
  • Biochemical response [ Time Frame: From date of randomization till 30 days safety fup, assessed up to 32 months (actual final OS analysis) ]
    Biochemical response is defined as the proportion of participants who have a greater or equal 50% decrease in PSA from Baseline that is confirmed by a second PSA measurement 4 weeks later
  • Prostate-specific antigen 80 (PSA80) response [ Time Frame: From date of randomization till 30 days safety fup, assessed up to 32 months (actual final OS analysis) ]
    PSA80 response is defined as the proportion of participants who have a greater or equal 80% decrease in PSA from Baseline that is confirmed by a second PSA measurement 4 weeks later
  • Duration of PSA response [ Time Frame: From date of randomization till 30 days safety fup, assessed up to 32 months (actual final OS analysis) ]
    Duration of PSA response is defined as the duration between the date of first document PSA response (i.e. >= 50% decrease in PSA from Baseline) and the earliest date of PSA progression
  • European Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L) [ Time Frame: From date of randomization till 30 days safety fup, assessed up to 32 months (actual final OS analysis) ]
    EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions.
  • Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire [ Time Frame: From date of randomization till 30 days safety fup, assessed up to 32 months (actual final OS analysis) ]
    FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT-General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.
  • Brief Pain Inventory-short Form (PBI-SF) [ Time Frame: From date of randomization till 30 days safety fup, assessed up to 32 months (actual final OS analysis) ]
    The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 [no pain] to 10 [pain as bad as you can imagine]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Official Title  ICMJE VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Brief Summary The primary objective of this study is to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone.
Detailed Description

Patients with PSMA positive scans will be randomized in a 2:1 ratio to receive either 177Lu-PSMA-617 plus best supportive/best standard of care or to receive best supportive/best standard of care only. Best supportive/best standard of care will be determined by the treating physician/investigator but will exclude investigational agents, cytotoxic chemotherapy, other systemic radioisotopes, and hemi-body radiotherapy. Novel androgen axis drugs [NAADs] (such as abiraterone or enzalutamide) are allowed.

The study is open-label and patients will be monitored throughout the 6 to 10-month treatment period for survival, disease progression, and adverse events.

A long-term follow-up period will include the collection of rPFS survival and information about new treatments, responses to new treatments, adverse events assessment, as well as blood for hematology and chemistry testing. During follow-up, patients will be contacted every 3 months (+/- 1 month) via phone, email, or letter for 24 months or until 508 deaths have occurred.

An End of Treatment visit should occur once a patient discontinues the treatment part of the study for any reason (patient or investigator decision, going on to long term follow up, etc.). This visit should occur approximately 30 days from the last dose of 177Lu-PSMA-617 or the date of the best supportive/best standard of care end of treatment decision (whichever occurs later), but before the initiation of subsequent anti-cancer treatment, outside of what is allowed on study.

The planned enrollment for this study is 814 patients.

A dosimetry, PK and ECG sub-study will be conducted in a non-randomized cohort (177Lu-PSMA-617 plus best supportive/best standard of care) of approximately 30 patients at sites in Germany to provide a more complete assessment of the safety aspects of 177Lu-PSMA-617. In order to not bias the results obtained from randomized patients in the main study, the data of the sub-study patients will be analyzed descriptively and not considered in the primary and secondary analysis of the main study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
The study population includes patients with progressive PSMA-positive mCRPC who received at least one novel androgen axis drug [NAAD] (such as enzalutamide or abiraterone) and were previously treated with 1 to 2 taxane regimens. Patients treated with only 1 prior taxane regimen are eligible if the patient is unwilling or the patient's physician deems the patient unsuitable to receive a second regimen.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Prostate Cancer
Intervention  ICMJE
  • Drug: 177Lu-PSMA-617
    administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients will be assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments are met the patient may receive an additional 2 cycles of 177Lu-PSMA-617.
  • Other: Best supportive/best standard of care
    Best supportive/best standard of care as defined by the local investigator
    Other Name: Comparator
Study Arms  ICMJE
  • Experimental: 177Lu-PSMA-617 plus BS/BSC
    Patients randomized to receive the investigational product will receive 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) may be used
    Interventions:
    • Drug: 177Lu-PSMA-617
    • Other: Best supportive/best standard of care
  • BS/BSC alone
    Patients randomized to this arm will receive best supportive/best standard of care (BS/BSOC) as determined by the investigator
    Intervention: Other: Best supportive/best standard of care
Publications * Iravani A, Violet J, Azad A, Hofman MS. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer Prostatic Dis. 2020 Mar;23(1):38-52. doi: 10.1038/s41391-019-0174-x. Epub 2019 Oct 8. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: March 23, 2021)
831
Original Estimated Enrollment  ICMJE
 (submitted: April 26, 2018)
750
Estimated Study Completion Date  ICMJE June 30, 2022
Actual Primary Completion Date January 27, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients must have the ability to understand and sign an approved ICF.
  2. Patients must have the ability to understand and comply with all protocol requirements.
  3. Patients must be ≥18 years of age.
  4. Patients must have an ECOG performance status of 0 to 2.
  5. Patients must have a life expectancy >6 months.
  6. Patients must have histological, pathological, and/or cytological confirmation of prostate cancer.
  7. Patients must be 68Ga-PSMA-11 PET/CT scan positive, and eligible as determined by the sponsor's central reader.
  8. Patients must have a castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L).
  9. Patients must have received at least one NAAD (such as enzalutamide and/or abiraterone).
  10. Patients must have been previously treated with at least 1, but no more than 2 previous taxane regimens. A taxane regimen is defined as a minimum exposure of 2 cycles of a taxane. If a patient has received only 1 taxane regimen, the patient is eligible if: a. The patient's physician deems him unsuitable to receive a second taxane regimen (e.g. frailty assessed by geriatric or health status evaluation, intolerance, etc.).
  11. Patients must have progressive mCRPC. Documented progressive mCRPC will be based on at least 1 of the following criteria:

    1. Serum/plasma PSA progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal start value is 2.0 ng/mL.
    2. Soft-tissue progression defined as an increase ≥20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions.
    3. Progression of bone disease: evaluable disease or new bone lesions(s) by bone scan (2+2 PCWG3 criteria, Scher et al 2016).
  12. Patients must have ≥1 metastatic lesion that is present on baseline CT, MRI, or bone scan imaging obtained ≤28 days prior to beginning study therapy.
  13. Patients must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies (i.e. prior chemotherapy, radiation, immunotherapy, etc.).
  14. Patients must have adequate organ function:

    a. Bone marrow reserve:

    • White blood cell (WBC) count ≥2.5 x 10^9/L (2.5 x 10^9/L is equivalent to 2.5 x 10^3/μL and 2.5 x K/μL and 2.5 x 10^3/cumm and 2500/μL) OR absolute neutrophil count (ANC) ≥1.5 x 10^9/L (1.5 x 10^9/L is equivalent to 1.5 x 10^3/μL and 1.5 x K/μL and 1.5 x 10^3/cumm and 1500/μL)
    • Platelets ≥100 x 10^9/L (100 x 10^9/L is equivalent to 100 x 10^3/μL and 100 x K/μL and 100 x 10^3/cumm and 100,000/μL)
    • Hemoglobin ≥9 g/dL (9 g/dL is equivalent to 90 g/L and 5.59 mmol/L) b. Hepatic:
    • Total bilirubin ≤1.5 x the institutional upper limit of normal (ULN). For patients with known Gilbert's Syndrome ≤3 x ULN is permitted
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3.0 x ULN OR ≤5.0 x ULN for patients with liver metastases c. Renal:
    • Serum/plasma creatinine ≤1.5 x ULN or creatinine clearance ≥50 mL/min
  15. Albumin >3.0 g/dL (3.0 g/dL is equivalent to 30 g/L) [Inclusion #16 has been removed]

17. HIV-infected patients who are healthy and have a low risk of AIDS-related outcomes are included in this trial.

18. For patients who have partners of childbearing potential: Partner and/or patient must use a method of birth control with adequate barrier protection, deemed acceptable by the principle investigator during the study and for 6 months after last study drug administration.

19. The best standard of care/ best supportive care options planned for this patient:

  1. Are allowed by the protocol
  2. Have been agreed to by the treating investigator and patient
  3. Allow for the management of the patient without 177Lu-PSMA-617

Exclusion Criteria:

  1. Previous treatment with any of the following within 6 months of randomization: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed.
  2. Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies]) within 28 days prior to day of randomization.
  3. Any investigational agents within 28 days prior to day of randomization.
  4. Known hypersensitivity to the components of the study therapy or its analogs.
  5. Other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy.
  6. Transfusion for the sole purpose of making a subject eligible for study inclusion.
  7. Patients with a history of CNS metastases must have received therapy (surgery, radiotherapy, gamma knife) and be neurologically stable, asymptomatic, and not receiving corticosteroids for the purposes of maintaining neurologic integrity. Patients with epidural disease, canal disease and prior cord involvement are eligible if those areas have been treated, are stable, and not neurologically impaired. For patients with parenchymal CNS metastasis (or a history of CNS metastasis), baseline and subsequent radiological imaging must include evaluation of the brain (MRI preferred or CT with contrast).
  8. A superscan as seen in the baseline bone scan.
  9. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
  10. Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation.
  11. Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, patients with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible, as are patients with adequately treated non-melanoma skin cancer, superficial bladder cancer.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
Gender Eligibility Description: Prostate cancer
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Canada,   Denmark,   France,   Germany,   Netherlands,   Puerto Rico,   Sweden,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03511664
Other Study ID Numbers  ICMJE PSMA-617-01
2018-000459-41 ( EudraCT Number )
CAAA617A12301 ( Other Identifier: Novartis )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Responsible Party Endocyte
Study Sponsor  ICMJE Endocyte
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
PRS Account Endocyte
Verification Date June 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP